number of epidemiological studies have documented that a high proportion of patients with chronic heart failure (CHF) has preserved left ventricular (LV) systolic function, and this condition is commonly referred to as diastolic heart failure (HF). 1 Excessive LV hypertrophy and development of fibrosis are associated with the onset of diastolic HF. The myocardial extracellular matrix is thought to play an important part in the pathogenesis of ventricular dilation, and the fibrillar extracellular matrix is mainly composed of types I and III fibrillar collagens forming a 3-dimensional framework, stabilizing the ventricular geometry and preserving the alignment of cardiomyocytes, which is important for normal LV function. 2 Although morbidity and mortality rates in diastolic HF are high, 1 most of the previous studies have focused on systolic HF, and clinical markers to predict adverse outcome have not yet been established for diastolic HF. Therefore, the aims of the present study were (1) to characterize the clinical features of CHF patients with preserved LV systolic function, and (2) 
Clinical characteristics of the study subjects are listed in Table 1 . The functional severity of CHF was New York Heart Association (NYHA) class II in 90, class III in 49, and class IV in 17 patients. The etiologies of CHF were dilated cardiomyopathy in 57 (37%), ischemic heart disease in 52 (33%), hypertensive heart disease in 29 (19%) , hypertrophic cardiomyopathy in 3 (2%), and others in 15 patients (9%). A history of hypertension was considered present if the patient was currently, or previously, on medical therapy for high blood pressure. A diagnosis of diabetes and hyperlipidemia was obtained from medical records or patient history. [3] [4] [5] [6] Blood samples were obtained at admission for measurement of serum ICTP concentrations. Physicians were kept unaware of the results of the biochemical markers, and optimal medical therapy was performed independently, based on improvement in symptoms, physical examination findings, and pulmonary congestion on chest X-ray.
Endpoints and Follow-up
No patients were lost to follow-up (mean follow-up 643± 354 days, range 5-1,095 days) after admission. Events were centrally adjudicated using medical records, autopsy reports, death certificates, and witness statements. The endpoints, which were judged independently by researchers, were (1) cardiac death, defined as death from worsening HF or sudden cardiac death, and (2) worsening HF requiring readmission. [3] [4] [5] [6] Sudden cardiac death was defined as death without definite premonitory symptoms or signs and was established by the attending physician.
Assay of ICTP Concentrations
Venous blood samples were immediately centrifuged at 2,500 G for 15 min at 4°C. The clarified serum samples were frozen, stored at -80°C, and thawed just before assay. ICTP concentrations were determined by radioimmunoassay as previously reported using a polyclonal antibody specifically directed against the ICTP (Orion Diagnostica, Finland). 7 The intra-and interassay variations for determining ICTP were <8%. The sensitivity (lower detection limit) was 0.5 ng/ml.
Echocardiography
Two-dimensional echocardiography was performed within 1 week after admission, using routine standard care by experts unaware of the study data. LV dimensions were measured by M-mode tracing, and the LV ejection fraction (LVEF) was calculated based on Simpson's rule. Pulsed Doppler wave examination of mitral inflow was performed in each subject as previously reported. 8 
Statistical Analysis
Results are presented as mean value ± SD for continuous variables and as the percentage of total patients for categorical variables. The t-test and chi-square test were used for comparison of continuous and categorical variables, respectively. The value below the lower detection limit of the assay was defined as 0. A Cox proportional hazard analysis was performed to determine the independent predictor of cardiac events for the entire population. Significant variables selected in the univariate analysis were entered into the multivariate analysis. The cardiac event-free curve was computed according to the Kaplan-Meier method and compared by the log-rank test. The receiver operating characteristic (ROC) curves were constructed to evaluate the area under the ROC curves (AUC). Statistical significance was determined at p<0.05. Statistical analysis was performed with a standard statistical program package (StatView, version 5.0, SAS Institute Inc, Cary, NC, USA). Table 1 summarizes the clinical backgrounds and characteristics of all patients. A simple linear regression analysis showed that serum ICTP concentrations were weakly correlated with the plasma brain natriuretic peptide (BNP) concentrations (R=0.307, p<0.001).
Results
All patients were divided into 4 groups based on the ICTP value: 1 st quartile (1.2-3.4 ng/ml, n=40), 2 nd quartile (3.5-4.6 ng/ml, n=39), 3 rd quartile (4.7-7.2 ng/ml, n=39), and 4 th quartile (7.3-19. 3 ng/ml, n=38). Table 2 summarizes the comparisons of the clinical characteristics of the 4 groups. NYHA functional class was more severe in the 3 rd and 4 th quartiles (p<0.05). There were 50 cardiac events (32%), including 19 cardiac deaths and 31 readmissions for worsening HF, during the follow-up period. The causes of cardiac death were worsening CHF in 13 patients and fatal (Fig 1) . Next, all patients were divided into 2 groups based on the LVEF on echocardiography: reduced LV systolic function group (LVEF <50%, n=92) and preserved LV systolic function group (LVEF ≥50%, n=64). Table 3 shows the comparison of the clinical backgrounds and characteristics of the 2 groups. The reduced LV systolic function group had a more severe NYHA functional class (p<0.01) and higher concentrations of uric acid (p<0.001), creatinine (p<0.05) and BNP (p<0.0001), a larger LV end-diastolic dimension (p<0.0001), and higher E/A ratio (p<0.01) than the preserved LV systolic function group. There were more patients with dilated cardiomyopathy in the reduced LV systolic function group (p<0.0001). In contrast, patients with hypertension (p<0.05) and hypertensive heart disease (p<0.0001) were more common in the preserved LV systolic function group. Concentration of ICTP was not significantly different between the reduced and preserved LV systolic function groups. As shown in Fig 2, Kaplan-Meier analysis demonstrated that cardiac event-free rates were significantly lower in the reduced LV systolic function group than in the preserved LV systolic function group (39% vs 22%, p=0.0134).
Next, we examined the predictive value of ICTP separately in the reduced and preserved LV systolic function groups. Patients in these function groups were divided into 2 groups based on the median value of ICTP for all patients (4.8 ng/ml). In the reduced LV systolic function group, Kaplan-Meier analysis demonstrated that the cardiac eventfree rates were not different between the high ICTP group (ICTP >4.8ng/ml) and the low ICTP group (ICTP <4.8ng/ml) ( Fig 3A) . However in the preserved LV systolic function group, the cardiac event-free rates were significantly lower in the high ICTP group (ICTP >4.8 ng/ml) than in the low ICTP group (ICTP <4.8 ng/ml) as shown in Fig 3B (p<  0.001) .
The ROC curves for ICTP to predict cardiac events at 36 months after admission in the reduced and preserved LV systolic function groups are shown in Fig 4. The AUC in the preserved LV systolic function group was markedly larger than that in the reduced LV systolic function group (0.881 vs 0.653), suggesting that ICTP can predict cardiac event more accurately in the preserved LV systolic function group than in the reduced LV systolic function group.
The ability of prognostic variables to predict cardiac events was examined by univariate and multivariate Cox pro- portional hazard analyses. In the reduced LV systolic function group, ICTP, common logarithm of BNP, creatinine, NYHA functional class, and age were associated with subsequent cardiac events in the univariate analysis (Table 4) . Therefore, these 5 variables were entered into the multivariate analysis. Creatinine (hazard ratio 1.435, 95% confidence interval (CI) 1.013-2.032, p<0.05) and common logarithm of BNP (hazard ratio 2.928, 95% CI 1.279-6.702, p<0.05) were independent predictors of cardiac events in the reduced LV function group in the multivariate analysis. Serum ICTP was not an independent predictor of cardiac events in the reduced LV systolic function group. In the preserved LV systolic function group, ICTP, common logarithm of BNP, creatinine, sodium, atrial fibrillation, NYHA functional class, and age were associated with subsequent cardiac events in the univariate analysis (Table 5) , so these 7 variables were entered into the multivariate analysis. Sodium (hazard ratio 0.871, 95% CI 0.76-0.996, p<0.05) and ICTP (hazard ratio 1.210, 95% CI 1.013-1.446, p<0.05) were independent predictors of cardiac events in the preserved LV systolic function group.
Discussion
The present study has demonstrated that the ICTP concentration at admission was independently associated with cardiac events in patients hospitalized for CHF, particularly those with preserved LV systolic function.
The 12-kDa ICTP, which results from the cleavage of Kaplan-Meier analysis of cardiac event-free rate in patients with chronic heart failure stratified into 2 groups based on the left ventricular ejection fraction (EF) by echocardiography (≥50% and <50%). collagen type I by collagenase, is found in an immunochemically intact form in blood. 9 On the basis of a number of clinical and experimental observations, it has been suggested that the serum concentration of ICTP reflects the rate of extracellular degradation of collagen type I. 7, 10 Diastolic dysfunction refers to an abnormality of LV diastolic relaxation and stiffness. 11 Myocardial stiffness is determined by ventricular fibrosis, and may be attributed to progressive collagen accumulation and a shift of the collagen phenotype from type III to type I, 12 indicating that the release of ICTP into circulation reflects ventricular fibrosis and myocardial stiffness associated with progression of HF, particularly diastolic dysfunction. In addition, it has been recently reported that the serum levels of ICTP are increased in patients with dilated cardiomyopathy, hypertrophic cardiomyopathy and untreated hypertension compared with normal patients. [13] [14] [15] Some studies have reported that there is a significant correlation between ICTP and the carboxyterminal propeptide of collagen type I (PIPC), a marker of collagen synthesis. 15 Treatment with loop diuretics, 16 and angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers 17 decreases the PIPC levels, despite the tendency toward increased ICTP in patients with CHF. The data suggest that these pharmacotherapies shift the balance toward degradation of collagen type I fibers and tend to restore the equilibrium between collagen type I synthesis and degradation, but the degree of increased ICTP is smaller Carboxy-terminal telopeptide of type I collagen in heart failure was evaluated for prediction of cardiac events in both the reduced and preserved left ventricular (LV) systolic function groups at 36 months after admission. Area under the ROC curve (AUC) was larger in the preserved than in the reduced LV systolic function group. EF, ejection fraction. Tables 1,3 .
compared with the degree of decreased PIPC. [16] [17] [18] [19] In the present study, we focused on collagen degradation rather than collagen synthesis and showed that ICTP, a marker of collagen type I degradation, was useful for determining the prognosis, particularly in HF patients with preserved LV systolic function. Although the American College of Cardiology/American Heart Association Guidelines state that the diagnosis of diastolic HF is generally based on the finding of typical symptoms and signs in a patient who is shown to have a normal LVEF and no valvular abnormalities on echocardiography, 20 there are not firm criteria for evaluating ventricular diastolic function at present. Therefore, we defined "HF with preserved LVEF (>50%)" as preserved LV systolic function in the present study.
BNP is a cardiac neurohormone specifically secreted from the ventricles. 21 Elevation of the plasma BNP level is considered to reflect ventricular structural and functional alterations. In addition, experimental studies have demonstrated that cardiac BNP expression is closely associated with LV systolic wall stress in HF. 22 Although its clinical utility as a biochemical marker of LV systolic dysfunction has been established, [23] [24] [25] it has been also recognized that impaired relaxation and/or compliance per se is not sufficient to trigger cardiac BNP secretion and BNP might be a suboptimal marker of diastolic dysfunction. [26] [27] [28] In the present study, BNP displayed a statistically significant correlation with cardiac events in the univariate analysis, but was not an independent predictor in the multivariate analysis of the preserved LV systolic function group. On the other hand, ICTP was an independent predictor of cardiac events by multivariate analysis in the preserved LV systolic function group (Table 5) . Furthermore, the AUC of ICTP was much larger in the preserved LV systolic function group than in the reduced LV systolic function group (Fig 4) , indicating that ICTP is superior for predicting cardiac events in patients with preserved LV systolic function.
In contrast, ICTP was not an independent predictor of cardiac events in the reduced LV systolic function group (Table 4) . Patients with dilated cardiomyopathy and myocardial infarction, most of whom were in the reduced LV systolic function group, suffer from left and/or right ventricular cardiomyocyte damage, leading to progressive cardiac enlargement and accumulation of fibrillar extracellular matrix, a process called cardiac remodeling. [29] [30] [31] Our data demonstrated that in the reduced LV systolic function group, cardiac event rates were not significantly different between patients with a high ICTP and those with a low ICTP (Fig 3A) . These results suggest that as an index of myocardial stiffness only, ICTP, was not sufficient to stratify cardiac events in the reduced LV systolic function group. In contrast, BNP was a useful marker for risk stratifying HF patients with reduced LV systolic function (Table 4) , as reported in many previous studies.
Conclusion
Although morbidity and mortality rates in diastolic HF are high, clinical markers to predict outcomes have not yet been established. The present study demonstrated the first evidence that the serum level of ICTP at admission may be a promising predictor of prognosis in CHF patients with preserved LV systolic function.
